Publicacións en colaboración con investigadores/as de University of Oxford (58)

2024

  1. Immunomodulatory leptin receptor+ sympathetic perineurial barrier cells protect against obesity by facilitating brown adipose tissue thermogenesis

    Immunity, Vol. 57, Núm. 1, pp. 141-152.e5

2023

  1. Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists

    Communications biology, Vol. 6, Núm. 1, pp. 376

  2. β-Peptides incorporating polyhydroxylated cyclohexane β-amino acid: synthesis and conformational study

    Organic and Biomolecular Chemistry, Vol. 21, Núm. 42, pp. 8535-8547

2022

  1. Collaboration and knowledge integration for successful brain therapeutics – lessons learned from the pandemic

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 12

  2. Stable d-xylose ditriflate in divergent syntheses of dihydroxy prolines, pyrrolidines, tetrahydrofuran-2-carboxylic acids, and cyclic β-amino acids

    Organic and Biomolecular Chemistry, Vol. 20, Núm. 47, pp. 9447-9459

2020

  1. Brain-Sparing Sympathofacilitators Mitigate Obesity without Adverse Cardiovascular Effects

    Cell Metabolism, Vol. 31, Núm. 6, pp. 1120-1135.e7

  2. Discovery of novel immunopharmacological ligands targeting the IL-17 inflammatory pathway

    International Immunopharmacology, Vol. 89

  3. Highly functionalized cyclic and bicyclic β−amino acids from sugar β−nitroesters

    Tetrahedron, Vol. 76, Núm. 3

2019

  1. #EUROmicroMOOC: using Twitter to share trends in Microbiology worldwide

    FEMS microbiology letters, Vol. 366, Núm. 11

  2. Central nicotine induces browning through hypothalamic κ opioid receptor

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Development of 8-pyridopyrimidinone-based covalent inhibitors of KDM5B

    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY

  2. Development of KDM5 covalent inhibitors as chemical probes

    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY

2017

  1. Gefitinib and EGFR gene copy number aberrations in esophageal cancer

    Journal of Clinical Oncology, Vol. 35, Núm. 20, pp. 2279-2287

  2. Solid sorbitan esters nanoparticles are efficient and low-cost vehicles for subunit vaccines: Proof of concept with Neisseria meningitidis protein Mip

    Journal of Drug Delivery Science and Technology, Vol. 42, pp. 299-306

2016

  1. IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 95, Núm. 5, pp. 1367-1377

  2. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond

    PLoS Pathogens, Vol. 12, Núm. 7

2015

  1. A stereoselective transformation of (-)-shikimic acid into (3R,4S,5R,7R)-7-(hydroxymethyl)azepane-3,4,5-triol, a potential glycosidase inhibitor

    Tetrahedron Asymmetry, Vol. 26, Núm. 5-6, pp. 320-323

2014

  1. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial

    The Lancet Oncology, Vol. 15, Núm. 8, pp. 894-904

2012

  1. Guidelines for the use and interpretation of assays for monitoring autophagy

    Autophagy, Vol. 8, Núm. 4, pp. 445-544

2009

  1. Proteomic analysis of HepaRG cells: A novel cell line that supports hepatitis B virus infection

    Journal of Proteome Research, Vol. 8, Núm. 1, pp. 118-122